{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T23:09:55Z","timestamp":1777158595726,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-025-05995-0","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T11:36:55Z","timestamp":1759750615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Monitoring fracture risk during antiosteoporotic therapy: a retrospective cohort study"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9899-7719","authenticated-orcid":false,"given":"Mariya","family":"Nedkova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5089-4925","authenticated-orcid":false,"given":"Tsvetanka","family":"Petranova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8030-0529","authenticated-orcid":false,"given":"Rositsa","family":"Karalilova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1233-5775","authenticated-orcid":false,"given":"Zguro","family":"Batalov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"5995_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(21)00172-0","author":"GBD 2019 Fracture Collaborators","year":"2021","unstructured":"GBD 2019 Fracture Collaborators (2021) Global, regional, and national burden of bone fractures in 204 countries and territories, 1990\u20132019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet Healthy Longev 2(9):e580\u2013e92 PubMed PMID: 34723233. https:\/\/doi.org\/10.1016\/S2666-7568(21)00172-0"},{"issue":"1","key":"5995_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11657-020-0706-y","volume":"15","author":"F Borgstrom","year":"2020","unstructured":"Borgstrom F, Karlsson L, Ortsater G, Norton N, Halbout P, Cooper C et al (2020) Fragility fractures in europe: burden, management and opportunities. Arch Osteoporos 15(1):59 PubMed PMID: 32306163; PubMed Central PMCID: PMCPMC7166207. https:\/\/doi.org\/10.1007\/s11657-020-0706-y","journal-title":"Arch Osteoporos"},{"key":"5995_CR3","unstructured":"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/fragility-fractures"},{"issue":"11","key":"5995_CR4","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00198-004-1627-0","volume":"15","author":"O Johnell","year":"2004","unstructured":"Johnell O, Kanis JA (2004) An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 15(11):897\u2013902","journal-title":"Osteoporos Int"},{"issue":"12","key":"5995_CR5","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17(12):1726\u20131733","journal-title":"Osteoporos Int"},{"issue":"22","key":"5995_CR6","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1056\/NEJMp1202619","volume":"366","author":"M Whitaker","year":"2012","unstructured":"Whitaker M, Guo J, Kehoe T, Benson G (2012) Bisphosphonates for osteoporosis\u2013where do we go from here? N Engl J Med 366(22):2048\u20132051","journal-title":"N Engl J Med"},{"issue":"22","key":"5995_CR7","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1056\/NEJMp1202623","volume":"366","author":"DM Black","year":"2012","unstructured":"Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ (2012) Continuing bisphosphonate treatment for osteoporosis\u2013for whom and for how long? N Engl J Med 366(22):2051\u20132053","journal-title":"N Engl J Med"},{"issue":"10","key":"5995_CR8","doi-asserted-by":"publisher","first-page":"711","DOI":"10.7326\/M14-0317","volume":"161","author":"CJ Crandall","year":"2014","unstructured":"Crandall CJ, Newberry SJ, Diamant A et al (2014) Comparative effectiveness of Pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med 161(10):711\u2013723","journal-title":"Ann Intern Med"},{"issue":"8","key":"5995_CR9","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1210\/jc.2008-2630","volume":"94","author":"BZ Leder","year":"2009","unstructured":"Leder BZ, Neer RM, Wyland JJ, Lee HW, Burnett-Bowie SM, Finkelstein JS (2009) Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab 94(8):2915\u20132921","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"5995_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","volume":"43","author":"PD Miller","year":"2008","unstructured":"Miller PD, Bolognese MA, Lewiecki EM et al (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43(2):222\u2013229","journal-title":"Bone"},{"key":"5995_CR11","doi-asserted-by":"publisher","first-page":"702261","DOI":"10.3389\/fendo.2021.702261","volume":"12","author":"F Lai","year":"2021","unstructured":"Lai F, Pei L, Chen X, Li J (2021) Osteoporosis-Related randomized clinical trials with Middle-Aged and older adults registered on the international clinical trials registry platform. Front Endocrinol 12:702261. https:\/\/doi.org\/10.3389\/fendo.2021.702261","journal-title":"Front Endocrinol"},{"key":"5995_CR12","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1007\/s00198-012-2030-x","volume":"23","author":"S Ferrari","year":"2012","unstructured":"Ferrari S, Bianchi ML, Eisman JA, Foldes AJ, Adami S, Wahl DA, Stepan JJ, de Vernejoul MC, Kaufman JM (2012) Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int 23:2735\u20132748. https:\/\/doi.org\/10.1007\/s00198-012-2030-x","journal-title":"Osteoporos Int"},{"issue":"5","key":"5995_CR13","doi-asserted-by":"publisher","first-page":"817e29","DOI":"10.1007\/s00198-020-05756-8","volume":"32","author":"AM Burden","year":"2021","unstructured":"Burden AM, Tanaka Y, Xu L et al (2021) Osteoporosis case ascertainment strategies in European and Asian countries: a comparative review. Osteoporos Int 32(5):817e29. https:\/\/doi.org\/10.1007\/s00198-020-05756-8","journal-title":"Osteoporos Int"},{"issue":"5","key":"5995_CR14","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00198-016-3894-y","volume":"28","author":"NC Harvey","year":"2017","unstructured":"Harvey NC, McCloskey EV, Mitchell PJ et al (2017) Mind the (treatment) gap: a global perspective on current and future stra Tegies for prevention of fragility fractures. Osteoporos Int 28(5):1507\u20131529. https:\/\/doi.org\/10.1007\/s00198-016-3894-y","journal-title":"Osteoporos Int"},{"issue":"3","key":"5995_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jocd.2017.06.008","volume":"20","author":"G El-Hajj Fuleihan","year":"2017","unstructured":"El-Hajj Fuleihan G, Chakhtoura M, Cauley JA et al (2017) Worldwide fracture prediction. J Clin Densitom: Official J Int Soc Clin Densitometry 20(3):397\u2013424. https:\/\/doi.org\/10.1016\/j.jocd.2017.06.008","journal-title":"J Clin Densitom: Official J Int Soc Clin Densitometry"},{"key":"5995_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40520-024-02826-3","volume":"36","author":"N Veronese","year":"2024","unstructured":"Veronese N, Briot K, Gua\u00f1abens N et al (2024) Recommendations for the optimal use of bone forming agents in osteoporosis. Aging Clin Exp Res 36:167. https:\/\/doi.org\/10.1007\/s40520-024-02826-3","journal-title":"Aging Clin Exp Res"},{"key":"5995_CR17","doi-asserted-by":"publisher","unstructured":"Carey J, Wu CH (\u5433\u81f3\u884c) (eds) (2022) Bergin D. Risk assessment tools for osteoporosis and fractures. Best Pract Res Clin Rheumatol 36(3):101775. https:\/\/doi.org\/10.1016\/j.berh.2022.101775","DOI":"10.1016\/j.berh.2022.101775"},{"issue":"3","key":"5995_CR18","doi-asserted-by":"publisher","first-page":"120e6","DOI":"10.1007\/BF01623272","volume":"3","author":"PD Ross","year":"1993","unstructured":"Ross PD, Genant HK, Davis JW et al (1993) Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporos Int 3(3):120e6. https:\/\/doi.org\/10.1007\/BF01623272","journal-title":"Osteoporos Int"},{"issue":"6","key":"5995_CR19","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00198-006-0306-8","volume":"18","author":"ES Siris","year":"2007","unstructured":"Siris ES, Genant HK, Laster AJ et al (2007) Enhanced prediction of fracture risk combining vertebral fracture status and BMD. Osteoporos Int 18(6):761\u2013770. https:\/\/doi.org\/10.1007\/s00198-006-0306-8","journal-title":"Osteoporos Int"},{"issue":"4","key":"5995_CR20","doi-asserted-by":"publisher","first-page":"57622","DOI":"10.52965\/001c.57622","volume":"14","author":"E Kirilova","year":"2022","unstructured":"Kirilova E, Kirilov N, Bischoff F et al (2022) Prevalence of low bone mineral density at axial sites and fracture risk in Bulgarian population. Orthop Rev 14(4):57622. https:\/\/doi.org\/10.52965\/001c.57622","journal-title":"Orthop Rev"},{"key":"5995_CR21","doi-asserted-by":"publisher","first-page":"1254e9","DOI":"10.1136\/bmj.312.7041.1254","volume":"312","author":"D Marshall","year":"1996","unstructured":"Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254e9. https:\/\/doi.org\/10.1136\/bmj.312.7041.1254","journal-title":"BMJ"},{"key":"5995_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","volume":"31","author":"JA Kanis","year":"2020","unstructured":"Kanis JA, Harvey NC, McCloskey E et al (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31:1\u201312. https:\/\/doi.org\/10.1007\/s00198-019-05176-3","journal-title":"Osteoporos Int"},{"key":"5995_CR23","doi-asserted-by":"publisher","unstructured":"Dimai HP (2017) Use of dual-energy X-ray absorptiometry (DXA) for diagnosis and fracture risk assessment; WHO-criteria, T and Z-score, and reference databases. Bone 104:39\u201343. https:\/\/doi.org\/10.1016\/j.bone.2016.12.016","DOI":"10.1016\/j.bone.2016.12.016"},{"key":"5995_CR24","unstructured":"Vladeva S, Bischoff E, Kirilov N et al (2022) Assessment of the radiofrequency echographic multi-spectrometry (REMS) based fragility score of the lumbar spine and total fracture risk at 5 years. Rheumatology International Manuscript number: RHEI-D-23-00814, electronic ISSN: 1437-160X, Scopus, IF 4.0"},{"issue":"10","key":"5995_CR25","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00198-021-05942-2","volume":"32","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Johansson H, Harvey NC et al (2021) An assessment of intervention thresholds for very high fracture risk applied to the noggguidelines: a report for the National osteoporosis guideline group (NOGG). Osteoporos Int 32(10):1951\u20131960. https:\/\/doi.org\/10.1007\/s00198-021-05942-2","journal-title":"Osteoporos Int"},{"issue":"4","key":"5995_CR26","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40520-022-02100-4","volume":"34","author":"EM Curtis","year":"2022","unstructured":"Curtis EM, Reginster JY, Al-Daghri N et al (2022) Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clin Exp Res 34(4):695\u2013714. https:\/\/doi.org\/10.1007\/s40520-022-02100-4","journal-title":"Aging Clin Exp Res"},{"key":"5995_CR27","doi-asserted-by":"publisher","unstructured":"Harvey H NC, An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis. J Endocrinol 33, Schini M et al (2024) Johansson Invest 47, 501\u2013511. https:\/\/doi.org\/10.1007\/s40618-023-02219-9","DOI":"10.1007\/s40618-023-02219-9"},{"issue":"5","key":"5995_CR28","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/jbmr\/zjae048","volume":"39","author":"S-AM Burnett-Bowie","year":"2024","unstructured":"Burnett-Bowie S-AM, Wright NC, Yu EW et al (2024) The American society for bone and mineral research task force on clinical algorithms for fracture risk report. J Bone Miner Res 39(5):517\u2013530. https:\/\/doi.org\/10.1093\/jbmr\/zjae048","journal-title":"J Bone Miner Res"},{"issue":"1","key":"5995_CR29","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","volume":"106","author":"E Tsourdi","year":"2021","unstructured":"Tsourdi E, Zillikens MC, Meier C et al (2021) Fracture risk and management of discontinuation of denosumab therapy: a Sys tematic review and position statement by ECTS. J Clin Endocrinol Metab 106(1):264\u2013281. https:\/\/doi.org\/10.1210\/clinem\/dgaa756","journal-title":"J Clin Endocrinol Metab"},{"key":"5995_CR30","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"CV Odvina","year":"2005","unstructured":"Odvina CV, Zerwekh JE, Rao DS et al (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294\u20131301. https:\/\/doi.org\/10.1210\/jc.2004-0952","journal-title":"J Clin Endocrinol Metab"},{"key":"5995_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2022.101780","author":"HP Dimai","year":"2022","unstructured":"Dimai HP, Fahrleitner-Pammer A (2022) Osteoporosis and fragility fractures: currently available pharmacological options and future directions. Best Pract Res Clin Rheumatol. https:\/\/doi.org\/10.1016\/j.berh.2022.101780. 36 101780","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"5995_CR32","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1007\/s00198-009-1168-7","volume":"21","author":"JJ Stepan","year":"2010","unstructured":"Stepan JJ, Burr DB, Li J et al (2010) Histomorphometric changes by teriparatide in alendronate-pretreated women with oste oporosis. Osteoporos Int 21:2027\u20132036. https:\/\/doi.org\/10.1007\/s00198-009-1168-7","journal-title":"Osteoporos Int"},{"key":"5995_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.bone.2013.11.011","volume":"59","author":"YL Ma","year":"2014","unstructured":"Ma YL, Zeng QQ, Chiang AY et al (2014) Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment. Bone 59:139\u2013147. https:\/\/doi.org\/10.1016\/j.bone.2013.11.011","journal-title":"Bone"},{"key":"5995_CR34","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1359\/jbmr.090527","volume":"24","author":"H Dobnig","year":"2009","unstructured":"Dobnig H, Stepan JJ, Burr DB et al (2009) Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. J Bone Min Res 24:1998\u20132006. https:\/\/doi.org\/10.1359\/jbmr.090527","journal-title":"J Bone Min Res"},{"key":"5995_CR35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bone.2016.05.004","volume":"89","author":"A Fahrleitner-Pammer","year":"2016","unstructured":"Fahrleitner-Pammer A, Burr D, Dobnig H et al (2016) Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment. Bone 89:16\u201324. https:\/\/doi.org\/10.1016\/j.bone.2016.05.004","journal-title":"Bone"},{"key":"5995_CR36","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00198-022-06626-1","volume":"34","author":"G Yu","year":"2023","unstructured":"Yu G, Tong S, Liu J et al (2023) A systematic review of cost-effectiveness analyses of sequential treatment for osteoporosis. Osteoporos Int 34:641\u2013658. https:\/\/doi.org\/10.1007\/s00198-022-06626-1","journal-title":"Osteoporos Int"},{"issue":"9","key":"5995_CR37","doi-asserted-by":"publisher","first-page":"e10665","DOI":"10.1002\/jbm4.10665","volume":"14","author":"JH Krege","year":"2022","unstructured":"Krege JH, Gilsenan AW, Komacko JL et al (2022) Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates. J Bone Min Res Plus 14(9):e10665. https:\/\/doi.org\/10.1002\/jbm4.10665","journal-title":"J Bone Min Res Plus"},{"key":"5995_CR38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00296-010-1586-z","volume":"31","author":"P Salari Sharif","year":"2011","unstructured":"Salari Sharif P, Abdollahi M, Larijani B (2011) Current, new and future treatments of osteoporosis. Rheumatol Int 31:289\u2013300. https:\/\/doi.org\/10.1007\/s00296-010-1586-z","journal-title":"Rheumatol Int"},{"issue":"1","key":"5995_CR39","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11914-020-00566-7","volume":"18","author":"EM Curtis","year":"2020","unstructured":"Curtis EM, Woolford S, Holmes C et al (2020) General and specific considerations as to why osteoporosis-related care is often suboptimal. Curr Osteoporos Rep 18(1):38\u201346. https:\/\/doi.org\/10.1007\/s11914-020-00566-7","journal-title":"Curr Osteoporos Rep"},{"key":"5995_CR40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bone.2017.01.024","volume":"104","author":"EM Curtis","year":"2017","unstructured":"Curtis EM, Moon RJ, Harvey NC, Cooper C (2017) The impact of fragility fracture and approaches to osteoporosis risk assessment worldwide. Bone 104:29\u201338. https:\/\/doi.org\/10.1016\/j.bone.2017.01.024","journal-title":"Bone"},{"key":"5995_CR41","doi-asserted-by":"publisher","first-page":"101759","DOI":"10.1016\/j.berh.2022.101759","volume":"36","author":"P Geusens","year":"2022","unstructured":"Geusens P, Appelman-Dijkstra NM, Zillikens MC et al (2022) How to implement guidelines and models of care. Best Pract Res Clin Rheumatol 36:101759. https:\/\/doi.org\/10.1016\/j.berh.2022.101759","journal-title":"Best Pract Res Clin Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05995-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-025-05995-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05995-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:02:41Z","timestamp":1761588161000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-025-05995-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["5995"],"URL":"https:\/\/doi.org\/10.1007\/s00296-025-05995-0","relation":{"references":[{"id-type":"doi","id":"10.1016\/S2666-7568(21)00172-0","asserted-by":"subject"}]},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest with respect to the authorship and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the ethical standards outlined in the Helsinki Declaration. It does not involve any interventional human studies carried out directly by the authors. The collection of anonymised patient data was approved by the Professional Ethics Commission of Medical Scientific Studies at Burgas State University \u201cProf. Dr. Asen Zlatarov\u201d (Protocol No. 4\/23.04.2025). The data presented in this study have not been previously published. Patient care was provided in accordance with the recommendations and guidelines outlined in \u201d\n                      Ethical Issues in Patient Safety Research: Interpreting Existing Guidance\n                      \u201d, as endorsed by the WHO.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}],"article-number":"244"}}